Cardiovascular events in patients with psoriasis and psoriatic arthritis treated with JAK/TYK inhibitors: A systematic review and meta-analysis
Corresponding Author
Marina Mordehachvili Burlá
Division of Medicine, Estácio de Sá Vista Carioca University, Rio de Janeiro, Brazil
Correspondence
Marina Mordehachvili Burlá, Division of Medicine, Estácio de Sá Vista Carioca University, Presidente Vargas Ave. 1111 Rio de Janeiro RJ, Brazil.
Email: [email protected]
Search for more papers by this authorIzabela Pera Calvi
Division of Clinical Neurosciences and Mental Health, University of Porto, Porto, Portugal
Search for more papers by this authorRegina Chahine Chater
Division of Medicine, Albert Einstein Israeli Faculty of Health Sciences, São Paulo, Brazil
Search for more papers by this authorRafaela de Moraes-Souza
Department of Dermatology, La Paz University Hospital, Madrid, Spain
Search for more papers by this authorVladimir V. Rafalskiy
Immanuel Kant Baltic Federal University, Kaliningrad, Russia
Search for more papers by this authorPedro Herranz-Pinto
Department of Dermatology, La Paz University Hospital, Madrid, Spain
Search for more papers by this authorGeorge Doumat
Department of Emergency Medicine, Massachusetts General Hospital, Boston, USA
Search for more papers by this authorMaria Tsoukas
Department of Dermatology, University of Illinois at Chicago, College of Medicine, Chicago, Illinois, USA
Search for more papers by this authorRoger Haber
Department of Dermatology, University of Illinois at Chicago, College of Medicine, Chicago, Illinois, USA
Search for more papers by this authorCorresponding Author
Marina Mordehachvili Burlá
Division of Medicine, Estácio de Sá Vista Carioca University, Rio de Janeiro, Brazil
Correspondence
Marina Mordehachvili Burlá, Division of Medicine, Estácio de Sá Vista Carioca University, Presidente Vargas Ave. 1111 Rio de Janeiro RJ, Brazil.
Email: [email protected]
Search for more papers by this authorIzabela Pera Calvi
Division of Clinical Neurosciences and Mental Health, University of Porto, Porto, Portugal
Search for more papers by this authorRegina Chahine Chater
Division of Medicine, Albert Einstein Israeli Faculty of Health Sciences, São Paulo, Brazil
Search for more papers by this authorRafaela de Moraes-Souza
Department of Dermatology, La Paz University Hospital, Madrid, Spain
Search for more papers by this authorVladimir V. Rafalskiy
Immanuel Kant Baltic Federal University, Kaliningrad, Russia
Search for more papers by this authorPedro Herranz-Pinto
Department of Dermatology, La Paz University Hospital, Madrid, Spain
Search for more papers by this authorGeorge Doumat
Department of Emergency Medicine, Massachusetts General Hospital, Boston, USA
Search for more papers by this authorMaria Tsoukas
Department of Dermatology, University of Illinois at Chicago, College of Medicine, Chicago, Illinois, USA
Search for more papers by this authorRoger Haber
Department of Dermatology, University of Illinois at Chicago, College of Medicine, Chicago, Illinois, USA
Search for more papers by this author
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
REFERENCES
- 1Gao N, Kong M, Li X, Zhu X, Wei D, Ni M, et al. The association between psoriasis and risk of cardiovascular disease: a mendelian randomization analysis. Front Immunol. 2022; 29(13):918224. https://doi.org/10.3389/fimmu.2022.918224
10.3389/fimmu.2022.918224 Google Scholar
- 2Garshick MS, Ward NL, Krueger JG, Berger JS. Cardiovascular risk in patients with psoriasis: JACC review topic of the week. J Am Coll Cardiol. 2021; 77(13): 1670–1680. https://doi.org/10.1016/j.jacc.2021.02.009
- 3Megna M, Potestio L, Ruggiero A, Cacciapuoti S, Maione F, Tasso M, et al. JAK inhibitors in psoriatic disease. Clin Cosmet Investig Dermatol. 2023; 16: 3129–3145. https://doi.org/10.2147/CCID.S433367
- 4Ingrassia JP, Maqsood MH, Gelfand JM, Weber BN, Bangalore S, Lo Sicco KI, et al. Cardiovascular and venous thromboembolic risk with JAK inhibitors in immune-mediated inflammatory skin diseases: a systematic review and meta-analysis. JAMA Dermatol. 2024; 160(1): 28–36. https://doi.org/10.1001/jamadermatol.2023.4090
- 5Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022; 386(4): 316–326. https://doi.org/10.1056/NEJMoa2109927
- 6Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther (Heidelb). 2023; 13(3): 729–749. https://doi.org/10.1007/s13555-023-00892-5
- 7Ireland PA, Jansson N, Spencer SKR, Braden J, Sebaratnam D. Short-term cardiovascular complications in dermatology patients receiving JAK-STAT inhibitors: a meta-analysis of randomized clinical trials. JAMA Dermatol. 2024; 160: 281–289. https://doi.org/10.1001/jamadermatol.2023.5509
- 8Masson W, Lobo M, Molinero G. Psoriasis and cardiovascular risk: a comprehensive review. Adv Ther. 2020; 37(5): 2017–2033. https://doi.org/10.1007/s12325-020-01346-6
- 9Wu JJ, Kavanaugh A, Lebwohl MG, Gniadecki R, Merola JF. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022; 36(6): 797–806. https://doi.org/10.1111/jdv.18044
- 10Weber B, Merola JF, Husni ME, Di Carli M, Berger JS, Garshick MS. Psoriasis and cardiovascular disease: novel mechanisms and evolving therapeutics. Curr Atheroscler Rep. 2021; 23(11): 67. https://doi.org/10.1007/s11883-021-00963-y
